| GPRO 1.23 40.38% | PCG 14.06 5.95% | LIDR 1.47 27.83% | NVDA 217.44 -1.51% | HKPD 0.1815 -45.54% | TSLL 9.33 -6.42% | NVD 4.05 3.05% | RITR 0.0882 -4.13% | NIO 4.055 -4.14% | FLYE 2.2 61.76% | INTC 88.97 -0.60% | ONDS 7.04 -8.05% | NU 14.46 -0.62% | BITO 10.38 -2.35% | RZLV 2.39 -17.30% | PATH 18.14 -2.84% | SOXL 105.91 -6.10% | AAL 12.95 -3.57% | NOK 9.93 -2.07% | TQQQ 69.15 -3.85% | SPCX 142.23 -1.02% | AAPL 325.13 2.61% | IBIT 43.76 -2.04% | F 13.83 -0.79% | HYG 79.1 -0.89% | SQQQ 39.97 3.79% | PLUG 2.09 -3.24% | SOXS 52.22 6.53% | BIAF 6.59 44.52% | SGOV 100.41 -0.28% | BTG 5.2 -5.11% | CDE 20.2 -2.79% | QID 14.59 2.53% | SOFI 17.05 -4.64% | PFE 28.55 0.32% | SPY 761.78 -0.69% | BMNR 23.37 -7.70% | GRAB 3.46 -2.26% | AIM 0.236 4.42% | RIG 5.92 1.89% | TSLA 356.09 -3.22% | FRVO 19.75 28.41% | LQD 105.22 -0.93% | QQQ 707.64 -1.27% | SSM 4.755 77.43% | IREN 36.82 -0.79% | ETHA 18.23 -2.62% | XLE 64.77 1.27% | T 26.015 0.48% | EWZ 36.57 1.50%

Raymond James Downgrades Weave on Timing of Catalysts and SMB Software Pressure

Raymond James downgraded Weave Communications (NYSE: WEAV) from Strong Buy to Outperform and lowered its price target to $10.00 from $12.00.

The firm said its longer-term thesis on Weave remained largely intact, but the rating change reflected the timing of expected catalysts and a more challenging environment for small and mid-sized business software companies. Raymond James noted that Weave continued to gain traction across several growth initiatives, including expansion into Specialty Medical, which had become its second-largest market by locations.

The analyst also pointed to progress in multi-office deployments, including a recently announced win covering more than 600 locations, and a growing pipeline for its AI receptionist and automation solution, TrueLark. Additional growth opportunities were seen through deeper integrations, improved product packaging, potential ARPC expansion via AI and payments offerings, and broader go-to-market partnerships.

While these initiatives were expected to take time to fully materialize, Raymond James said it still saw a path toward re-accelerating growth and a return to a more consistent beat-and-raise pattern. The firm added that although shares traded at just 2x its 2026 sales estimate, a full re-rating was unlikely until organic growth acceleration became more visible or the company demonstrated a clearer glide path toward long-term profitability.

Published on: January 6, 2026